因賽集團(300781.SZ):2022年汽車品牌客户包括:上汽通用雪佛蘭、別克、吉利等獨立汽車品牌及旗下車型品牌
格隆匯5月11日丨因賽集團(300781.SZ)在5月11日15:00至17:00業績説明會表示,公司從2020年開始大力開拓汽車營銷業務,經過兩年多的開拓突破、深耕發展,基本確立了公司在汽車品牌營銷領域的專業領先優勢和聲譽。2022年,公司全面服務的汽車品牌客户包括:上汽通用雪佛蘭、別克、飛凡、吉利、幾何、哪吒汽車、比亞迪、東風風神、嵐圖汽車、廣汽汽車、YoYo汽車等獨立汽車品牌及旗下車型品牌。2022年,公司的汽車營銷業務收入(不含媒介代理業務)約6,940萬元,較上年同期增長超過50%,其中,新能源汽車營銷業務收入佔比約60%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.